Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics director Avraham Ben-Tzvi reported new equity awards. On January 20, 2026, he received 25,000 shares of restricted common stock as compensation under a consulting agreement, and these shares vested in full immediately upon grant. Following this award, he beneficially owns 25,100 shares of Indaptus common stock, including 100 shares held in a Roth IRA.
Separately, on December 23, 2025, he was granted options to purchase 25,000 shares of Indaptus common stock under the company’s non-employee director compensation program. These stock options vest over three years in equal quarterly installments, so long as he continues to serve on the board through each vesting date.
Indaptus Therapeutics director David Natan received a new stock option grant covering 25,000 shares of common stock. The options have an exercise price of $2.69 per share and were granted on January 7, 2026 under the company’s non-employee director compensation program. The award vests over three years in equal quarterly installments starting from the grant date, as long as Natan continues to serve on the board through each vesting date. Following this grant, he beneficially holds 25,000 stock options directly.
Indaptus Therapeutics has called a February 26, 2026 special meeting to ask stockholders to approve a transformative recapitalization built around a recent $6.0 million preferred stock investment by David E. Lazar. The company sold 300,000 Series AA and 700,000 Series AAA Convertible Preferred shares at $6.00 each; after stockholder approval these can convert into 111.0 million common shares. Based on 2,242,324 common shares outstanding as of January 21, 2026, full conversion would give the new investor about 96.4% of the fully diluted common, sharply diluting existing holders and concentrating voting power. Proposals also include electing two Lazar nominees to the board, authorizing a reverse stock split in a 1‑for‑2 to 1‑for‑199 range, increasing authorized common from 200,000,000 up to 1,000,000,000 shares, permitting stockholder action by written consent, and related Nasdaq change of control and issuance approvals.
Indaptus Therapeutics, Inc. reported changes to executive compensation and board composition. The company entered into salary adjustment agreements with Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman, Ph.D. Effective January 15, 2026, each executive’s salary was set at $60,000 per year for the remainder of the year, paid according to the company’s standard payroll practices.
The company also disclosed that board member Anthony Maddaluna, who had previously notified the company of his intention to resign as of the next special meeting of stockholders, has rescinded that resignation. He will remain on the Board of Directors and continue to serve on the Compensation Committee and Nominating Committee.
Indaptus Therapeutics, Inc. director David Natan filed an initial ownership report stating that he currently holds no shares of the company. The filing shows that he has no beneficial ownership of non-derivative or derivative securities of Indaptus as of the event date, and his position is reported as a director filing on his own behalf.
Indaptus Therapeutics, Inc. expanded its Board of Directors from eight to nine members and appointed David Natan to fill the new seat. He was named a Class II director with a term running until the 2026 annual meeting of stockholders, when he will stand for election. Natan was designated by David E. Lazar under a securities purchase agreement dated December 22, 2025.
Natan brings extensive finance and public company experience, including leadership roles at multiple companies and service on other public boards and audit committees. He was also appointed to the Audit Committee, replacing Avraham Ben-Tzvi, who will remain on the board and is expected to serve as a paid consultant. The board determined that Natan qualifies as an independent director and meets Nasdaq’s heightened independence standards for audit committee service. He will participate in the company’s non-employee director compensation program.
Indaptus Therapeutics, Inc. entered into a Securities Purchase Agreement with David E. Lazar, under which he bought 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock at $6.00 per share for total gross proceeds of $6.0 million. After stockholder approval, these preferred shares will be convertible into a combined 111,000,000 shares of common stock, and Lazar also receives the right to purchase up to 25% of certain future equity offerings during a six‑month participation period.
The deal is paired with major governance changes: Lazar becomes Chairman and Co‑Chief Executive Officer, and Avraham Ben‑Tzvi joins the board, filling seats of two resigning directors who left without disagreements. Executive officers agreed to modified employment terms, including reduced notice periods and a mix of cash and stock settlements, and the Chief Medical Officer resigned with a cash bonus payment. New certificates of designation give the preferred stock senior liquidation preference and limited voting rights, while a voting agreement commits key executives to support board‑recommended proposals at an upcoming special stockholder meeting.
Indaptus Therapeutics (INDP) filed its Q3 2025 10‑Q, reporting a net loss of $2,975,117 for the quarter and $12,736,466 for the nine months ended September 30, 2025. Operating expenses were $2,648,487 in Q3, with R&D at $1,517,723 and G&A at $1,130,764. Cash and cash equivalents were $5,825,639 at quarter‑end.
The company states there is substantial doubt about its ability to continue as a going concern. Management believes current cash funds operations into the first quarter of 2026 and is pursuing additional financing. During 2025, Indaptus raised capital via a $20.0 million SEPA (net proceeds approximately $1.74 million to date), $5.7 million of convertible notes (automatically converted on July 27, 2025 into 501,566 shares and pre‑funded warrants), and an ATM sale of 520,000 shares for net proceeds of about $2.25 million in September.
The company effected a 1‑for‑28 reverse stock split on June 26, 2025, regaining Nasdaq bid‑price compliance. Shares outstanding were 1,641,920 as of September 30, 2025; as context, 1,751,163 were outstanding as of November 11, 2025. Indaptus continues Phase 1 development of Decoy20, including a combination study with tislelizumab, and has paused further enrollment pending additional efficacy evaluations.
Indaptus Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025. The company states that the full text of this earnings press release is provided as Exhibit 99.1 and is incorporated by reference. Indaptus clarifies that the information in this report, including the exhibit, is being furnished rather than filed, which limits its exposure to certain Exchange Act liabilities. The report is signed on behalf of the company by its Chief Financial Officer, Nir Sassi.
Indaptus Therapeutics, Inc. filed a current report to note that on September 4, 2025 it issued a press release with recent updates on its ongoing INDP-D101 clinical trial. The press release is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed clinical information is contained in that separate document. The report is signed on behalf of the company by Chief Financial Officer Nir Sassi.